Loss of SMN Impairs Osteoblast–Osteoclast Coupling via IGF1 –Akt– OPG Axis in Spinal Muscular Atrophy
The FASEB Journal · 31.10.2025 · 39 (20)
DOI: 10.1096/fj.202501626r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, erschienen am 31.10.2025. Verfasst von Taiyang Xiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor I, Osteoclasts, Proto-Oncogene Proteins c-akt, Osteoblasts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Nature Science Foundation of China, the Key Medical Discipline of Jiangsu Province, the Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Recent advancements in therapeutics have extended lifespan and improved neurodevelopmental outcomes in spinal muscular atrophy (SMA) patients, particularly with severe phenotypes. However, most patients fail to achieve normal motor function. Although structural bone defects and increased fracture susceptibility have been reported in both SMA patients and mouse models, the role of survival motor neuron (SMN) protein in bone homeostasis and therapeutic targets remains incompletely understood. To investigate the function of SMN in bone metabolism, a mild SMA mouse model and Smn1 conditional knockout mice in the myeloid lineage and mature osteoclasts were utilized. Bone architecture was assessed using micro‐computed tomography (micro‐CT), histological staining, and immunohistochemistry. RNA sequencing was performed to explore molecular mechanisms underlying skeletal defects. Primary bone marrow mesenchymal stem cells (BMSCs) and bone marrow‐derived macrophages (BMMs) were differentiated into osteoblasts and osteoclasts, respectively, and co‐cultured to evaluate SMN‐dependent regulation of osteoblast–osteoclast interactions. The therapeutic potential of exogenous osteoprotegerin (OPG) administration was further assessed. SMA mice exhibited significant bone mass reduction, characterized by impaired osteogenesis and increased osteoclastogenesis. However, in vitro experiments revealed suppressed osteoclast differentiation in BMMs from SMA mice, which was inconsistent with in vivo findings. Co‐culture studies demonstrated that osteoclast hyperactivity in SMA mice resulted from decreased osteoblast‐derived OPG, induced by local insulin‐like growth factor 1 (IGF1) deficiency. Mechanistically, SMN depletion led to IGF1 downregulation, thereby suppressing PI3K‐Akt signaling, reducing OPG expression, and ultimately disrupting osteoblast–osteoclast coupling. Administration of exogenous OPG effectively mitigated osteoclast differentiation and resorptive activity, indirectly promoting osteoblast function and partially restoring bone formation. These findings reveal that SMN protein loss caused IGF1 deficiency that inhibited the PI3K‐Akt signaling pathway, leading to downregulation of OPG expression and disrupted osteoblast–osteoclast coupling. This study highlights the therapeutic potential of targeting OPG in SMA to alleviate skeletal complications and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Department of Neurology, Children's Hospital of Soochow University, Suzhou, Jiangsu, China.
ORCID-Profile: Lei Sheng
Förderung
- National Nature Science Foundation of China
- the Key Medical Discipline of Jiangsu Province
- the Natural Science Foundation of Jiangsu Province
- the Science and Technology Project of Suzhou
- the Gusu Talent Program
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Science and Technology Program of Suzhou
Zitieren
APA
Xiang, T., Zhou, Z., Li, Y., Suo, Y., Dai, J., Shi, X., Zhou, X., & Sheng, L. (2025). Loss of SMN Impairs Osteoblast–Osteoclast Coupling via IGF1 –Akt– OPG Axis in Spinal Muscular Atrophy. The FASEB Journal. https://doi.org/10.1096/fj.202501626r
Vancouver
Xiang T, Zhou Z, Li Y, Suo Y, Dai J, Shi X, et al. Loss of SMN Impairs Osteoblast–Osteoclast Coupling via IGF1 –Akt– OPG Axis in Spinal Muscular Atrophy. The FASEB Journal. 2025. doi:10.1096/fj.202501626r
BibTeX
@article{Xiang2025,
author = {Xiang, Taiyang and Zhou, Zijie and Li, Yaoyao and Suo, Yinxuan and Dai, Jun and Shi, Xiaoyan and Zhou, Xiaozhong and Sheng, Lei},
title = {Loss of SMN Impairs Osteoblast–Osteoclast Coupling via IGF1 –Akt– OPG Axis in Spinal Muscular Atrophy},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202501626r}
}
EUVIMED